Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 6 of 39 for:    alzheimer vaccine

18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease (FUNDAMANT)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Axon Neuroscience SE Identifier:
First received: January 7, 2014
Last updated: July 15, 2016
Last verified: July 2016

This follow-up study continues to observe patients who have completed the phase 1 trial of AADvac1, for another 18 months.

Long-term safety and behavior of the immune response to AADvac1 over time are the main points of interest.

AADvac1 is a vaccine directed against pathologically modified Alzheimer tau protein that is the main constituent of neurofibrillary tangles (NFTs), and is intended to be a disease-modifying treatment for Alzheimer's disease, i.e. to halt its progress.

As this study is a Phase I study focused on tolerability and safety, efficacy will be assessed in an exploratory manner.

Condition Intervention Phase
Alzheimer's Disease
Drug: AADvac1
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An 18-months Open Label Phase I Follow-up Study on Patients With Alzheimer's Disease Who Have Completed the AADvac1 Phase I Study "AXON CO 18700"

Resource links provided by NLM:

Further study details as provided by Axon Neuroscience SE:

Primary Outcome Measures:
  • Tolerability and safety profile of AADvac1 in patients with mild-to-moderate Alzheimer's disease [ Time Frame: Tolerability & safety are assessed over a period of 18+ months ] [ Designated as safety issue: Yes ]

    Safety is assessed via recording of all Adverse Events and Adverse Events

    Patients are observed via:

    MRI Clinical & neuro-psychiatric observation Cognitive testing ECG Blood biochemistry, hematology, coagulation measurement Urine analysis

Secondary Outcome Measures:
  • Immunogenicity of AADvac1 [ Time Frame: Immune response to the vaccine will be assessed over 18 month ] [ Designated as safety issue: No ]

    Measurement of:

    Titres of antibodies reactive with AADvac1 Titres of antibodies reactive with Alzheimer tau protein Antibody isotype profiles

  • Patient cognition [ Time Frame: 18+ months ] [ Designated as safety issue: Yes ]

    Tests used:

    ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive subscale) COWAT (Controlled oral word association test) Category fluency

Enrollment: 25
Study Start Date: January 2014
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AADvac1

Patients who have received 6 doses in the previous trial will be administered 1-2 booster doses of AADvac1 (2 if their antibody titers decline below those achieved in the previous trial).

Patients who have received 3 doses in the previous trial will be administered another 3 doses, then vaccinated with booster doses as above.

Drug: AADvac1
Active immunization against pathological Alzheimer's disease tau protein
Other Names:
  • Axon peptide 108 (coupled to KLH), 40ug/0.3mL
  • Axon peptide 108 conjugated to KLH

Detailed Description:

AADvac1 is a candidate therapeutic vaccine for Alzheimer's disease that targets misfolded tau protein, a common denominator of neurofibrillary pathology. Based on preclinical results, the intervention is expected to reduce the number of neurofibrillary tangles, remove hyperphosphorylated tau protein and reduce the amount of oligomerized and insoluble pathological tau in the brain, to halt the spread of neurofibrillary pathology through the brain, and thus prevent associated cognitive decline.

The vaccine's antigenic determinant is a synthetic peptide derived from a tau protein sequence, which is coupled to keyhole limpet hemocyanin (KLH) and uses aluminum hydroxide (Alhydrogel) as an adjuvant.

At present AADvac1 is intended as an active immunotherapy for patients with diagnosed Alzheimer's disease (AD). According to need, patients will receive additional immunization doses beyond those administered in the preceding pase 1 trial; the raised titers of therapeutic antibodies and possible benefits of the treatment can extend beyond the duration of the study.

Because of the central role of pathological misfolded tau protein in the etiology of AD, the vaccine is expected to be more effective than active or passive immunotherapies aiming to eliminate the amyloid β plaques that have been clinically investigated so far.


Ages Eligible for Study:   50 Years to 86 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Completion of visit V8 of the AADvac1 phase I study AXON CO 18700 (EUDRACT 2012-003916-29).
  2. Informed consent capability (as determined by an independent neurologist/psychiatrist).
  3. Written informed consent signed and dated by the patient and the caregiver.
  4. Availability of a partner/caregiver knowing the patient and being able to accompany the patient to the visits
  5. Adequate visual and auditory abilities and language skills to allow neuropsychological testing.
  6. Female patients are only eligible for the study if they are either surgically sterile or at least 2 years postmenopausal.
  7. Sexually active males must be using reliable contraception methods (i.e. condoms) or be surgically sterile.

Exclusion Criteria:

  1. Pregnant women.
  2. Participation in another clinical trial during the course of this study.
  3. Contraindication for MRI imaging such as MRI-incompatible metallic endoprosthesis or MRI-incompatible stent implantation
  4. History and/or presence of autoimmune disease, if considered relevant by the investigator.
  5. Significant systemic illness (e.g., chronic renal failure, chronic liver disease, poorly controlled diabetes, poorly controlled congestive heart failure, congenital long QT syndrome, other deficiencies), if considered relevant by the investigator.
  6. Current treatment with immunosuppressive drugs.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02031198

Medizinische Universitat Graz
Graz, Steiermark, Austria, 8036
Univeristätsklinik für Neurologie, PMU, Christian-Doppler Klinik
Salzburg, Austria, 5020
Medizinische Universitat Wien
Wien, Austria, 1090
Sozialmedizinisches Zentrum Ost (SMZ Ost) /Donauspital, Memory Clinic and Karl Landsteiner Institut for Amnestic disorders
Wien, Austria, A-1220
Sponsors and Collaborators
Axon Neuroscience SE
Principal Investigator: Reinhold Schmidt, Professor Medizinische Universität Graz
  More Information

Responsible Party: Axon Neuroscience SE Identifier: NCT02031198     History of Changes
Other Study ID Numbers: AC-AD-002  2013-004499-36 
Study First Received: January 7, 2014
Last Updated: July 15, 2016
Health Authority: Austria: Agency for Health and Food Safety

Keywords provided by Axon Neuroscience SE:
Alzheimer's disease
disease modifying

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders processed this record on September 30, 2016